FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2396838044> ?p ?o ?g. }

• W2396838044 endingPage "419" @default.
• W2396838044 startingPage "409" @default.
• W2396838044 abstract "Natural surfactant (Surfactant TA, Survanta, CLSE, SF-RI 1, Curosurf and human surfactant obtained from amniotic fluid) therapy for RDS in very premature infants has been evaluated in 17 controlled clinical trials. Uniformly intratracheal surfactant administration caused a decreased intensity of mechanical ventilation during the first hours (reduced inspiratory pressure, reduced oxygen requirements) as an immediate effect of surfactant administration. Metanalysis reveals barotraumatic pulmonary complications mainly, pneumothorax and pulmonary interstitial emphysema to occur less frequently in surfactant-treated infants in virtually all trials; an increased incidence of survival without bronchopulmonary dysplasia following surfactant treatment was observed in 10 controlled clinical trials. The incidence of other complications of prematurity (intracranial hemorrhage, patent ductus arteriosus and necrotizing enterocolitis) was unchanged following natural surfactant treatment. Dosing of natural surfactant is still under investigation, however recent data indicate that the initial dose should not be less than 100 mg/kg b.w. and retreatment should be given to infants with unsatisfactory response (i.e. fraction of inspired oxygen (FiO2) > 40%). Timing of surfactant treatment still remains controversial. Prophylactic treatment shortly following birth has been compared with rescue-treatment, i.e. surfactant administration to infants suffering from manifest RDS in most studies 4-8 h after birth. Conflicting data from 5 controlled trials may be interpreted as follows: prophylactic treatment seems to be favourable for extremely premature infants (GA < or = 26 weeks) and rescue treatment seems to be adequate for infants of 27-30 weeks of gestation. Intratracheal surfactant instillation in very premature infants did not result in an improved lung function for 24 h to 48 h in all patients. Ten--25% of study infants were reported to be non-responders, i.e. infants without sustained decrease in oxygen requirements (i.e. FiO2 > 40%). Various factors may be operative including congenital bacterial infections (sepsis or pneumonia), lung hypoplasia and cardiac failure. Inactivation of surface properties of natural surfactant caused by a leakage of proteins across the alveolar-capillary membrane was observed in experimental and clinical studies. Current investigations focus on a combination of postnatal steroids and surfactant treatment to improve lung function and outcome in non-responders. As long as any controlled clinical studies are being published, this approach remains experimental. Up to now, any controlled clinical trials have been performed to assess different modes of artificial ventilation (e.g. high frequency oscillating ventilation versus conventional ventilation) combined with surfactant therapy. Data obtained from premature animals given natural surfactant indicate any advantage with respect to gas exchange and lung histology to result from high frequency ventilation.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W2396838044 created "2016-06-24" @default.
• W2396838044 creator A5078918901 @default.
• W2396838044 date "1992-01-01" @default.
• W2396838044 modified "2023-10-14" @default.
• W2396838044 title "Review article" @default.
• W2396838044 cites W1491490119 @default.
• W2396838044 cites W1508001209 @default.
• W2396838044 cites W1511986979 @default.
• W2396838044 cites W1522502345 @default.
• W2396838044 cites W1537904609 @default.
• W2396838044 cites W1543428015 @default.
• W2396838044 cites W1574105203 @default.
• W2396838044 cites W1577789707 @default.
• W2396838044 cites W1586153322 @default.
• W2396838044 cites W1664126158 @default.
• W2396838044 cites W1668395980 @default.
• W2396838044 cites W1724529511 @default.
• W2396838044 cites W1831926862 @default.
• W2396838044 cites W1949192308 @default.
• W2396838044 cites W1987357229 @default.
• W2396838044 cites W198791171 @default.
• W2396838044 cites W1993973130 @default.
• W2396838044 cites W2000480240 @default.
• W2396838044 cites W2000939818 @default.
• W2396838044 cites W2004119748 @default.
• W2396838044 cites W2004419310 @default.
• W2396838044 cites W2004503153 @default.
• W2396838044 cites W2019314640 @default.
• W2396838044 cites W2022498186 @default.
• W2396838044 cites W2030269002 @default.
• W2396838044 cites W2037966074 @default.
• W2396838044 cites W2038849402 @default.
• W2396838044 cites W2043555498 @default.
• W2396838044 cites W2066789314 @default.
• W2396838044 cites W2076737839 @default.
• W2396838044 cites W2081757454 @default.
• W2396838044 cites W2084887794 @default.
• W2396838044 cites W2089949767 @default.
• W2396838044 cites W2091743074 @default.
• W2396838044 cites W2092357496 @default.
• W2396838044 cites W2153001272 @default.
• W2396838044 cites W2169502257 @default.
• W2396838044 cites W2224771663 @default.
• W2396838044 cites W2608558944 @default.
• W2396838044 cites W4206522872 @default.
• W2396838044 cites W4247280124 @default.
• W2396838044 cites W4295094128 @default.
• W2396838044 cites W4312562261 @default.
• W2396838044 cites W2339007256 @default.
• W2396838044 doi "https://doi.org/10.1515/jpme.1992.20.6.409" @default.
• W2396838044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1293266" @default.
• W2396838044 hasPublicationYear "1992" @default.
• W2396838044 type Work @default.
• W2396838044 sameAs 2396838044 @default.
• W2396838044 citedByCount "8" @default.
• W2396838044 crossrefType "journal-article" @default.
• W2396838044 hasAuthorship W2396838044A5078918901 @default.
• W2396838044 hasConcept C121332964 @default.
• W2396838044 hasConcept C126322002 @default.
• W2396838044 hasConcept C141071460 @default.
• W2396838044 hasConcept C2776953283 @default.
• W2396838044 hasConcept C2777050789 @default.
• W2396838044 hasConcept C2777080012 @default.
• W2396838044 hasConcept C2777714996 @default.
• W2396838044 hasConcept C2778329176 @default.
• W2396838044 hasConcept C2778376644 @default.
• W2396838044 hasConcept C2778721537 @default.
• W2396838044 hasConcept C2779234561 @default.
• W2396838044 hasConcept C2779252433 @default.
• W2396838044 hasConcept C2779303187 @default.
• W2396838044 hasConcept C2780807750 @default.
• W2396838044 hasConcept C42219234 @default.
• W2396838044 hasConcept C46973012 @default.
• W2396838044 hasConcept C535046627 @default.
• W2396838044 hasConcept C54355233 @default.
• W2396838044 hasConcept C58226133 @default.
• W2396838044 hasConcept C71924100 @default.
• W2396838044 hasConcept C86803240 @default.
• W2396838044 hasConcept C97355855 @default.
• W2396838044 hasConceptScore W2396838044C121332964 @default.
• W2396838044 hasConceptScore W2396838044C126322002 @default.
• W2396838044 hasConceptScore W2396838044C141071460 @default.
• W2396838044 hasConceptScore W2396838044C2776953283 @default.
• W2396838044 hasConceptScore W2396838044C2777050789 @default.
• W2396838044 hasConceptScore W2396838044C2777080012 @default.
• W2396838044 hasConceptScore W2396838044C2777714996 @default.
• W2396838044 hasConceptScore W2396838044C2778329176 @default.
• W2396838044 hasConceptScore W2396838044C2778376644 @default.
• W2396838044 hasConceptScore W2396838044C2778721537 @default.
• W2396838044 hasConceptScore W2396838044C2779234561 @default.
• W2396838044 hasConceptScore W2396838044C2779252433 @default.
• W2396838044 hasConceptScore W2396838044C2779303187 @default.
• W2396838044 hasConceptScore W2396838044C2780807750 @default.
• W2396838044 hasConceptScore W2396838044C42219234 @default.
• W2396838044 hasConceptScore W2396838044C46973012 @default.
• W2396838044 hasConceptScore W2396838044C535046627 @default.
• W2396838044 hasConceptScore W2396838044C54355233 @default.

• next